Ulixertinib
Ulixertinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target mitogen-activated protein kinase 3 and mitogen-activated protein kinase 1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
14 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 1 | — | — | 1 | 4 |
| Glioma | D005910 | EFO_0000520 | — | 3 | — | — | — | 3 | |
| Colorectal neoplasms | D015179 | — | 1 | — | — | 1 | 2 | ||
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | 1 | 2 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 1 | — | — | 1 | 2 |
| Head and neck neoplasms | D006258 | — | 1 | — | — | 1 | 2 | ||
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 1 | — | — | 1 | 2 | |
| Esophageal neoplasms | D004938 | C15 | — | 1 | — | — | 1 | 2 | |
| Urinary bladder neoplasms | D001749 | C67 | — | 1 | — | — | 1 | 2 | |
| Melanoma | D008545 | — | 1 | — | — | 1 | 2 |
Show 33 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | — | — | 1 | 1 | ||
| Glioblastoma | D005909 | EFO_0000515 | — | — | — | — | 1 | 1 | |
| Cholangiocarcinoma | D018281 | C22.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ULIXERTINIB |
| INN | ulixertinib |
| Description | Ulixertinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target mitogen-activated protein kinase 3 and mitogen-activated protein kinase 1. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors: epidermal growth factor receptor (EGFR) inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1 |
Identifiers
| PDB | — |
| CAS-ID | 869886-67-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3590106 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 16ZDH50O1U (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
MAPK3
MAPK3
MAPK1
MAPK1
Organism
Homo sapiens
Gene name
MAPK3
Gene synonyms
ERK1, PRKM3
NCBI Gene ID
Protein name
mitogen-activated protein kinase 3
Protein synonyms
ERK-1, ERT2, Extracellular signal-regulated kinase 1, extracellular signal-related kinase 1, Insulin-stimulated MAP2 kinase, MAP kinase isoform p44, MAPK 1, Microtubule-associated protein 2 kinase, p44-ERK1, p44-MAPK
Uniprot ID
Mouse ortholog
Mapk3 (26417)
mitogen-activated protein kinase 3 (Q91YW5)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 410 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more